Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference
Tourmaline Bio (NASDAQ: TRML), a late-stage clinical biotechnology company focused on developing transformative medicines for immune and inflammatory diseases, has announced its upcoming participation in the Guggenheim Securities SMID Cap Biotech Conference in New York.
The company's Co-Founder and CEO, Sandeep Kulkarni, MD, will participate in a fireside chat scheduled for Wednesday, February 5, 2025, at 1:30 pm ET. Investors and interested parties can access both the live webcast and replay of the presentation through the 'Events and Presentations' section on Tourmaline Bio's investor relations website at ir.tourmalinebio.com.
Tourmaline Bio (NASDAQ: TRML), una società biotecnologica clinica in fase avanzata concentrata nello sviluppo di farmaci trasformativi per le malattie immunitarie e infiammatorie, ha annunciato la sua prossima partecipazione alla Guggenheim Securities SMID Cap Biotech Conference a New York.
Il Co-Fondatore e CEO dell'azienda, Sandeep Kulkarni, MD, parteciperà a un incontro informale programmato per mercoledì 5 febbraio 2025, alle 13:30 ET. Gli investitori e le parti interessate possono accedere sia al webcast dal vivo che alla registrazione della presentazione attraverso la sezione 'Eventi e Presentazioni' sul sito web delle relazioni con gli investitori di Tourmaline Bio all'indirizzo ir.tourmalinebio.com.
Tourmaline Bio (NASDAQ: TRML), una compañía de biotecnología en etapa avanzada enfocada en desarrollar medicamentos transformadores para enfermedades inmunitarias e inflamatorias, ha anunciado su participación en la Guggenheim Securities SMID Cap Biotech Conference en Nueva York.
El Co-Fundador y CEO de la compañía, Sandeep Kulkarni, MD, participará en un chat informal programado para miércoles 5 de febrero de 2025, a la 1:30 pm ET. Los inversores y partes interesadas pueden acceder tanto a la transmisión en vivo como a la repetición de la presentación a través de la sección 'Eventos y Presentaciones' en el sitio web de relaciones con inversores de Tourmaline Bio en ir.tourmalinebio.com.
투어말린 바이오 (NASDAQ: TRML), 면역 및 염증 질환을 위한 혁신적인 의약품 개발에 집중하는 후기 단계 임상 생명공학 회사가 뉴욕에서 열리는 구겐하임 증권 SMID 캡 생명공학 컨퍼런스에 참가할 예정이라고 발표했습니다.
회사의 공동 창립자이자 CEO인 산딥 쿨카르니, MD가 2025년 2월 5일 수요일, 오후 1시 30분 ET에 예정된 대화에 참여할 것입니다. 투자자 및 관련자는 투어말린 바이오의 투자자 관계 웹사이트인 ir.tourmalinebio.com의 '이벤트 및 발표' 섹션을 통해 라이브 웹캐스트 및 발표 재생을 모두 이용할 수 있습니다.
Tourmaline Bio (NASDAQ: TRML), une entreprise de biotechnologie en phase clinique avancée spécialisée dans le développement de médicaments transformateurs pour les maladies immunitaires et inflammatoires, a annoncé sa participation prochaine à la Guggenheim Securities SMID Cap Biotech Conference à New York.
Le cofondateur et PDG de l'entreprise, Sandeep Kulkarni, MD, participera à une discussion informelle prévue pour le mercredi 5 février 2025, à 13h30 ET. Les investisseurs et les parties intéressées peuvent accéder à la diffusion en direct et à la rediffusion de la présentation via la section 'Événements et Présentations' sur le site web des relations investisseurs de Tourmaline Bio à l'adresse ir.tourmalinebio.com.
Tourmaline Bio (NASDAQ: TRML), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, das sich auf die Entwicklung transformierender Medikamente für Immun- und Entzündungserkrankungen spezialisiert hat, hat seine bevorstehende Teilnahme an der Guggenheim Securities SMID Cap Biotech Conference in New York bekannt gegeben.
Der Mitbegründer und CEO des Unternehmens, Sandeep Kulkarni, MD, wird an einem geplanten Gespräch am Mittwoch, den 5. Februar 2025, um 13:30 Uhr ET teilnehmen. Investoren und interessierte Parteien können sowohl auf den Live-Webcast als auch auf die Wiederholung der Präsentation über den Bereich 'Veranstaltungen und Präsentationen' auf der Investor-Relations-Website von Tourmaline Bio unter ir.tourmalinebio.com zugreifen.
- None.
- None.
NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the following investor conference:
Guggenheim Securities SMID Cap Biotech Conference, New York
Fireside Chat
Wednesday, February 5, 2025, at 1:30 pm ET
A live webcast and replay, when available, will be available under "Events and Presentations" in the News & Investors section of the Tourmaline Bio website at ir.tourmalinebio.com.
About Tourmaline Bio
Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline’s lead asset is pacibekitug (also referred to as TOUR006). For more information about Tourmaline Bio and pacibekitug, please visit https://www.tourmalinebio.com or follow us on LinkedIn or X.
Media Contact
Scient PR
Sarah Mishek
SMishek@ScientPR.com
Investor Contact
Meru Advisors
Lee M. Stern
lstern@meruadvisors.com
FAQ
When is Tourmaline Bio (TRML) presenting at the Guggenheim Securities SMID Cap Biotech Conference?
How can investors watch Tourmaline Bio's (TRML) Guggenheim Securities conference presentation?
What type of diseases does Tourmaline Bio (TRML) focus on treating?
What is the format of Tourmaline Bio's (TRML) presentation at the Guggenheim conference?
